Laura Deming is the CEO and co-founder of Until. She is also a full-time Partner at The Longevity Fund, an early-stage venture capital fund that invests in companies targeting the aging process to treat disease, including those focused on gene editing, small molecule therapeutics, and novel treatment methods.

Deming's passion for slowing aging and eliminating age-related disease began at a young age. She started working in a biogerontology lab at 12 and matriculated at MIT when she was 14.